ReviewMycoses2022
Collateral consequences of agricultural fungicides on pathogenic yeasts: A One Health perspective to tackle azole resistance.
Review in Mycoses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Molecular basis of azole fungicide interactions with human estrogen receptor alpha (ERα): an integrated in silico and in vitro toxicological assessment.Archives of toxicology · 2026Article
- Agricultural fungicides shape soil and sediment reservoirs of multidrug-resistant fungi.Nature communications · 2026Article
- Incidence of azole resistance among clinical isolates ofNew microbes and new infections · 2026Article
- Avian Candidiasis: A Comprehensive Review of Pathogenesis, Diagnosis, and Control.Veterinary sciences · 2026Review
- Yeast community associated with winter wheat leaves and its sensitivity to fungicides.Scientific reports · 2026Article
- Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026Review
- Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.npj antimicrobials and resistance · 2025Review
- Retrospective Multicenter Study on Invasive Candidiasis in Türkiye Demonstrates High Genetic Variety of Candida tropicalis.Mycopathologia · 2025Article
- Exploring the Androgen Receptor Binding Affinity of Azole Derivatives through Multiscale Computational and Experimental Approaches.Environmental science & technology · 2025Article
- Resistance of ERG24 sterol C-14 reductase to heterocyclic amine antifungals.npj antimicrobials and resistance · 2025Article
- Trichosporon and Antifungal Resistance: Current Knowledge and Gaps.Mycopathologia · 2025Review
- The Burden of Neonatal Invasive Candidiasis in Low- and Middle-income Countries: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2025Article
- Review
- Antifungal Drug Resistance.Current topics in microbiology and immunology · 2025Review
- Research progress on the drug resistance mechanisms ofFrontiers in microbiology · 2025Review
- From crops to clinic: the impact of dual azole use on antifungal resistance inFrontiers in microbiology · 2025Review
- Article
- The Human Mycobiome.Current topics in microbiology and immunology · 2025Review
- Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost.Nature microbiology · 2024Article
- Precise genome editing underlines the distinct contributions of mutations inAntimicrobial agents and chemotherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 7 countries.
Funding
Abstract
Candida and Cryptococcus affect millions of people yearly, being responsible for a wide array of clinical presentations, including life-threatening diseases. Interestingly, most human pathogenic yeasts are not restricted to the clinical setting, as they are also ubiquitous in the environment. Recent studies raise concern regarding the potential impact of agricultural use of azoles on resistance to medical antifungals in yeasts, as previously outlined with Aspergillus fumigatus. Thus, we undertook a narrative review of the literature and provide lines of evidence suggesting that an alternative, environmental route of azole resistance, may develop in pathogenic yeasts, in addition to patient route. However, it warrants sound evidence to support that pathogenic yeasts cross border between plants, animals and humans and that environmental reservoirs may contribute to azole resistance in Candida or other yeasts for humans. As these possibilities could concern public health, we propose a road map for future studies under the One Health perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.